ADAR1 Capital Management’s Astria Therapeutics ATXS Stock Holding History

ADAR1 Capital Management’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-173,557	Closed	-$2.27M	–	311
2025 Q4	$2.27M	Sell	173,557 -20,377	-11%	-$243K	0.17%	93
2025 Q3	$1.41M	Sell	193,934 -55,712	-22%	-$377K	0.13%	94
2025 Q2	$1.34M	Sell	249,646 -392,044	-61%	-$1.9M	0.21%	71
2025 Q1	$3.43M	Buy	641,690 +550,706	+605%	+$3.85M	0.64%	46
2024 Q4	$813K	Sell	90,984 -2,300	-2%	-$24.4K	0.16%	91
2024 Q3	$1.03M	Sell	93,284 -44,874	-32%	-$499K	0.17%	76
2024 Q2	$1.26M	Buy	138,158 +133,506	+2,870%	+$1.3M	0.24%	58
2024 Q1	$65.5K	Sell	4,652 -186,599	-98%	-$2.32M	0.01%	167
2023 Q4	$1.47M	Buy	+191,251	New	+$1.06M	0.52%	36

ADAR1 Capital Management's ATXS Position: Q1 2026 in Review

ADAR1 Capital Management sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 173,557 shares — an estimated $2.27M sold.

ADAR1 Capital Management first reported a position in ATXS in Q4 2023 and held it in 9 quarters. The position peaked at $3.43M in Q1 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

ADAR1 Capital Management reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
ADAR1 Capital Management sold 173,557 Astria Therapeutics shares in Q1 2026, an estimated $2.27M.
ADAR1 Capital Management first reported a position in Astria Therapeutics in Q4 2023 and held it in 9 quarters.
ADAR1 Capital Management's Astria Therapeutics position peaked at $3.43M in Q1 2025.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.